BioNTech’s transformation from a pandemic-era vaccine champion into a fully-fledged oncology powerhouse is proceeding at full throttle. The pipeline is expanding, the cash pile is massive, and a $1 billion buyback is underway. Yet the stock refuses to budge. At Friday’s close of €78.10, the shares trade 26% below the January high of €105.80 and roughly 9% beneath their 200-day moving average. The contrast between scientific momentum and market indifference has become the defining feature of the investment case.
The company’s oncology ambitions are no longer just talk. Over the past two years, BioNTech has more than doubled its number of Phase 2 and Phase 3 oncology studies, with more than 25 now active. By year-end, management plans to launch six additional Phase 3 trials, bringing the total to 15. Seven late-stage data readouts are expected in the second half of 2026 alone. Among them: Phase 2 results for Trastuzumab Pamirtecan in HER2-expressing endometrial cancer, Phase 3 data for Gotistobart in non-small cell lung cancer, and a pivotal readout for the mRNA therapy BNT113 in head and neck tumors. BioNTech aims to file a regulatory application for Trastuzumab Pamirtecan in endometrial cancer before 2026 is out.
The recent ASCO conference in Chicago provided a taste of that progress. Data for Pumitamig — a dual PD-L1/VEGF-A inhibitor developed with Bristol Myers Squibb — showed consistent anti-tumor activity in first-line non-small cell lung cancer. Gotistobart delivered durable responses in heavily pre-treated patients with platinum-resistant ovarian cancer, offering a chemotherapy-free option. The results were “encouraging” and “consistent,” but not decisive. They support the strategy without forcing a re-rating.
Financially, BioNTech is in an enviable position for a clinical-stage biotech. At year-end 2025, the company held €17.2 billion in cash and securities; by the end of the first quarter 2026, that had edged down to €16.8 billion as research spending continued. The R&D budget for 2026 stands at up to €2.5 billion, while full-year revenue guidance of €2.0–2.3 billion reflects the ongoing decline of Comirnaty sales. First-quarter 2026 revenue came in at €118.1 million, with a net loss of €531.9 million. No oncology product revenue is expected this year. Still, the balance sheet eliminates any need for dilutive capital raises — a luxury that most peers lack.
Management reinforced its conviction on June 8 by launching a share buyback of up to $1 billion, set to run through May 2027. The message is clear: they see value at current levels. That signal arrives alongside a significant leadership transition. Founders Ugur Sahin and Özlem Türeci plan to spin out a new entity focused on next-generation mRNA technologies, with BioNTech retaining a minority stake. Binding contracts are expected by the end of June. Such a change can inject uncertainty, but it may also allow a new executive team to pursue the oncology strategy without distraction.
Should investors sell immediately? Or is it worth buying BioNTech?
Analysts see the current price as deeply undervalued. The consensus target of €106.18 implies a 36% upside. Citi describes BioNTech as a “differentiated player among traditional vaccine names” that is “continuing its transformation into a commercial oncology company.” The bull case rests on the second-half data readouts proving that the pipeline can generate regulatory-grade results.
Technically, the stock is in no-man’s land. At €78.10, it sits below the 50-day average of €81.09, the 100-day of €84.40, and the 200-day of €85.61. The relative strength index of 48.8 signals neither overbought nor oversold. The 52-week low of €68.35 from March has held, giving the shares a 14% cushion — a sign that the worst of the revaluation may be behind them.
Macro forces could provide a tailwind. The Federal Reserve meets in mid-June, and after three rate cuts in 2025, further easing would benefit biotech stocks directly. Janus Henderson portfolio managers noted in their 2026 outlook that healthcare stocks trade at some of the lowest relative valuations in the sector’s history, even as fundamentals improve. That broader backdrop may lift BioNTech where ASCO alone could not.
For investors with a longer horizon, the risk-reward equation is shifting. The €16.8 billion cash pile buys time, the pipeline is generating real data, and the stock is priced for failure. Whether that gap closes depends on the seven readouts still to come. Until then, BioNTech remains a test of conviction — backed by substance, but waiting for proof.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 14 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 14.
BioNTech: Buy or sell? Read more here...
